Patents Assigned to Cellular Biomedicine Group, Inc.
  • Reagent and method for fluorescence quantitative real-time PCR detection of RCL
    Patent number: 11697848
    Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: July 11, 2023
    Assignee: Cellular Biomedicine Group, Inc.
    Inventors: Fang Liu, Liping Lan, Yutian Wei, Xun Ye, Li Zhang, Jiaqi Huang, Yihong Yao
  • Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
    Patent number: 11633430
    Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: April 25, 2023
    Assignee: CELLULAR BIOMEDICINE GROUP, INC.
    Inventors: Yihong Yao, Yanfeng Li, Yutian Wei, Shigui Zhu, Xin Yao, Jiaqi Huang
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11618778
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: April 4, 2023
    Assignee: CELLULAR BIOMEDICINE GROUP INC.
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11608369
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: March 21, 2023
    Assignee: Cellular Biomedicine Group, Inc.
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He